









Markets
/
Stocks
/
nasdaq-scni
/

Scinai Immunotherapeutics Ltd

SCNI



View Detailed Chart

0.750USD

-0.012-1.57%

Close 12/24, 13:00（ET）Quotes delayed by 15 min

1.14MMarket Cap

0.07P/E TTM



Scinai Immunotherapeutics Ltd

0.750

-0.012-1.57%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

-1.57%

5 Days

+1.35%

1 Month

-18.79%

6 Months

-68.35%

Year to Date

-77.58%

1 Year

-77.61%

View Detailed Chart

TradingKey Stock Score of Scinai Immunotherapeutics Ltd

Currency: USD Updated: 2025-12-24

Key Insights

Scinai Immunotherapeutics Ltd's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 234/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Scinai Immunotherapeutics Ltd's Score

Industry at a Glance

Industry Ranking

234 / 404

Overall Ranking

472 / 4562

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Scinai Immunotherapeutics Ltd Highlights

StrengthsRisks

Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.

Growing

The company is in a growing phase, with the latest annual income totaling USD 658.00K.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Fairly Valued

The company’s latest PE is 0.07, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 247.18K shares, increasing 45.83% quarter-over-quarter.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.81.